Piramal Pharma Ltd

Piramal Pharma Capital Structure Change

HDFC Mutual Fund schemes reduced their Piramal Pharma stake by 2.027% via open market sale on 28 October 2026. Holding fell from 7.015% to 4.988%.

Piramal Pharma Investor Presentation: Key Takeaways

Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.

Piramal Pharma Results Update

Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.

Piramal Pharma Q2 FY27 Results: Turns Profitable, Net Profit ₹5 Cr

Piramal Pharma Ltd reported revenue from operations of ₹2,617 Cr (+28.1% YoY) and net profit of ₹5 Cr for Q2 FY27.

Key figure

Net profit ₹5 Cr

Piramal Pharma Other Announcement

The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.

Piramal Pharma Board Meeting Date

Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.

Piramal Pharma Adverse Business Impact

Piramal Pharma announced that its sales and distribution arrangement with Bayer Pharmaceuticals will expire on December 31, 2026, and will not be renewed.

From

Bayer Pharmaceuticals Private Limited

Piramal Pharma Price Movement Clarification

Piramal Pharma clarified a news item regarding a $1.7 million (₹11.39 Cr) investment from the Government of Ontario, stating it does not require material disclosure.

Value

₹11.39 Cr

Piramal Pharma Price Movement Clarification

Piramal Pharma clarified that funding support from the Government of Ontario for its Aurora facility is not a material event requiring disclosure.

Value

₹0.17 Cr

Piramal Pharma Management Change

Piramal Pharma Limited announced the appointment of Mr. Brian Guy as President and COO of Piramal Critical Care. He succeeds Mr. Jeffrey Hampton, who is retiring.

Piramal Pharma Legal & Regulatory

Piramal Pharma Limited received a GST demand and equivalent penalty totaling Rs. 8.12 Crore from tax authorities. The company intends to appeal the order, contesting the eligibility of certain input tax credits.

Value

₹8.12 Cr

Piramal Pharma Other Announcement

Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.

Piramal Pharma Business Update

Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.